|
|
 |
 |
|
Faculty
Thomas Kodadek
Professor
Department of Chemistry
TSRI - 2009
Joint Appointments Cancer Biology
Education
B.S.(Chemistry) University of Miami (FL).
Ph.D. (Organic Chemistry) Stanford University (Advisors: James Collman, John Brauman).
Post-doctoral (Biochemistry) UCSF (Advisor: Bruce Alberts).
Awards & Activities
NIH Director’s Pioneer Award (2006-2011)
Fellow of the AAAS (elected 1999)
Jane Coffin Childs Postdoctoral Fellow (1985-1987)
American Cancer Society Junior Faculty Research Award (1989-1991)
Co-Editor of Jan. 2000, Feb. 2005 Issues of Current Opinion In Chemical Biology
Vice Chair (2002) and Chair (2004), Gordon Conference Chem. and Biol. of Peptides
Member (2000-2004) and Chair (2002-2004) of the NIH BNP Study Section.
Member, Nucleic Acids Study Section, American Cancer Society (1995-98).
Member, DOE special study section for materials science research (1994).
Member of the American Chemical Society, AAAS, Royal Society of Chemistry.
Steering Committee Member, NIH Chemistry Assistant Professor Mentoring Workshops
Member, Scientific Advisory Board of Stratagene Inc., La Jolla, CA
Member, Scientific Advisory Board, Receptors, LLC, Chaska, MN
Member, Scientific Advisory Board of Ra Pharmaceuticals, Cambridge, MA
Member, Scientific Advisory Board of Opko Health, Miami, FL
Co-Chair, NHLBI Committee for Strategic Planning in Emerging Technologies (2006)
Board Member, U.S. HUPO Coordinating Committee (2007)
Member, NIH committee on the Future of the Roadmap (2006)
Member, Special Study Section for NIH Director’s Innovator Awards (2007-8)
Editorial Boards
Chief of the Editorial Board Molecular BioSystems (Royal Society of Chemistry)
Chemistry & Biology (1/98-Present)
Associate Editor, Chemistry & Biology (6/99-5/03)
Chemtracts-Organic Chemistry (1/97-7/01)
Research Focus
The Kodadek Laboratory focuses on understanding and manipulating biological pathways important in various disease states. Our approach relies heavily on chemical methods and a major goal in each of the biological areas of interest is to develop compounds that serve as leads for drug development or can be employed as tools for mechanistic studies. The three areas of biology currently under investigation are: 1) autoimmune diseases and lymphomas, 2) the involvement of the proteasome in transcription and 3) the function of the hormone orexin in narcolepsy, diabetes and other diseases.
Selected References
Udugamasooriya, D.G., Dineen, S.P., Brekken, R.A. and Kodadek, T. (2008) “A peptoid “antibody surrogate” that antagonizes VEGF Receptor 2 activity” J. Amer. Chem. Soc. 130, 5744-52.
Archer, C.T., Burdine, L., Liu, B., Ferdous, A., Johnston, S.A. and Kodadek, T. (2008) Physical and functional interaction of mono-ubiquitylated transactivators with the proteasome” J. Biol. Chem. 283, 21789-21798.
Sikder, D. and Kodadek, T. (2007) “The neurohormone orexin stimulates hypoxia-inducible factor-1 activity” Genes & Devel. 21, 2995-3005.
Ferdous, A., Sikder, D., Gillette, T., Nalley, K., Kodadek, T. and Johnston, S.A. (2007) “The Role of the Proteasomal ATPases and Activator Mono-Ubiquitylation in Regulating Gal4 Binding to Promoters” Genes & Dev. 21, 112-123.
|
|
|
|
